Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis

[1]  T. Berg,et al.  Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. , 2017, Journal of hepatology.

[2]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[3]  P. Marcellin,et al.  Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open- , 2017, The lancet. Gastroenterology & hepatology.

[4]  S. Lim,et al.  When can we stop nucleoside analogues in patients with chronic hepatitis B? , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[5]  M. Buti,et al.  Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa‐2a combination therapy for chronic hepatitis B , 2016, Alimentary pharmacology & therapeutics.

[6]  S. Kottilil,et al.  Eradication Strategies for Chronic Hepatitis B Infection. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  N. Terrault,et al.  AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.

[8]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[9]  K. Simon,et al.  Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study) , 2015, Hepatology.

[10]  M. Buti,et al.  Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years , 2015, Hepatology International.

[11]  P. Marcellin,et al.  Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients , 2013, Hepatology International.

[12]  D. Vassilopoulos,et al.  Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. , 2012, Gastroenterology.

[13]  Jia-Horng Kao,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.

[14]  P. Marcellin,et al.  Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients , 2012, Hepatology International.

[15]  Y. Paik,et al.  Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg‐positive chronic hepatitis B , 2010, Hepatology.

[16]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[17]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[18]  E. Schiff,et al.  Durability of serologic response after lamivudine treatment of chronic hepatitis B , 2003, Hepatology.

[19]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[20]  M. Buti,et al.  Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. , 2016, Gastroenterology.